New facility will create more than 110 new jobs in Philly
Philadelphia, October 9, 2015 – Alan Greenberger, Deputy Mayor for Economic Development, announced on behalf of Mayor Michael A. Nutter that British life sciences company Adaptimmune will locate its U.S. headquarters and Clinical and Manufacturing Operations at the Philadelphia Navy Yard. The 47,400-square-foot facility is being developed by Liberty Property Trust and Synterra Partners and will house a state-of-the-art manufacturing facility designed to support the clinical development and initial commercialization of Adaptimmune’s engineered immunotherapies for cancer.
“Adaptimmune’s decision to expand in Philadelphia is further evidence of our city’s reputation as a leading place for technology, innovation and life sciences,” said Alan Greenberger, Deputy Mayor for Economic Development. “Companies large and small from around the region, and increasingly around the world, are seeing Philadelphia as the place they need to be in order to attract talent, grow their business, and build their brands.”
Established in 2008 in Oxford, U.K., Adaptimmune collaborated with the University of Pennsylvania before launching its own U.S. operation in February 2011. The Company rapidly expanded its clinical programs while operating out of the University City Science Center, Philadelphia, and is currently running trials for multiple types of cancer across the U.S. In May 2015, Adaptimmune achieved a successful IPO on NASDAQ, generating net proceeds in excess of $176M, and is advancing a promising pipeline of therapeutic candidates based on its proprietary T-cell engineering platform.
“This exciting new Philadelphia facility allows us to expand our clinical and manufacturing operations and prepare for the commercialization of our product candidates,” said James Noble, Chief Executive Officer of Adaptimmune. “We are delighted to be working in partnership with key players in Pennsylvania and we regard our commitment to The Navy Yard as a vote of confidence in the city and the region as a powerhouse for scientific and medical achievement.”
Adaptimmune is the latest company to announce expansion at the Philadelphia Navy Yard which has the region’s premier innovation, business, and life sciences campus. Just last month Axalta Coating Systems announced that it will locate its Global Innovation Center at the Navy Yard creating almost 200 new jobs in Philadelphia by 2018.
“From its inception, Adaptimmune has been at the forefront of innovation in the life sciences, and we are delighted that the company has expanded its U.S. headquarters and manufacturing operations in Philadelphia,” said John Grady, President of PIDC, Philadelphia’s public-private economic development corporation. “We look forward to Adaptimmune joining an inspiring, collaborative community at The Navy Yard.”
Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor platform. Established in 2008, the Company aims to utilize the body’s own machinery—the T-cell—to target and destroy cancer cells by using engineered, increased affinity T-cell receptors (TCRs) as a means of strengthening natural patient T-cell responses. Adaptimmune’s lead program is an affinity enhanced TCR therapeutic targeting the NY-ESO cancer antigen. Its NY-ESO TCR therapeutic candidate has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types. In June 2014, Adaptimmune announced that it had entered into a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO TCR program. The Company currently has over 150 employees world-wide. For more information:http://www.adaptimmune.com